Announced last year, the new life science campus will be built alongside the Stevenage Bioscience Catalyst – an organization which provides a supportive environment for companies to develop and commercialize advanced therapeutics– and GSK’s existing Global R&D center. It is expected to cover around 1.4 million square feet of laboratory and office facilities with space for up to 5,000 new jobs.
The campus, which is backed by UBS Asset Management and Reef, intends to help meet the growing demand for state-of-the-art commercial and laboratory space from both emerging and established life science firms.
The CGT Catapult is an independent innovation and technology organization committed to advancing cell and gene therapies, which works with government agency Innovate UK.
“The Catapult has already played a significant role in establishing the largest cell and gene therapy cluster in Europe in the UK, centred on its Manufacturing Innovation Centre (MIC) in Stevenage," says the organization.
"The MHRA licensed Stevenage MIC, which incorporates 12 segregated independent GMP cleanroom modules, was established in 2018 and has excellent international connectivity and supply chain links, an optimum skills base and a supportive environment for collaborators to grow.
“This latest agreement will ensure that the CGT Catapult remains within the Stevenage campus and also provides the potential for further expansion of its development, manufacturing and skills facilities in order to continue to drive innovation and growth in both the Stevenage cluster and the UK advanced therapy sector as a whole.”